Drug Combination Details
| General Information of the Combination (ID: C72772) | |||||
|---|---|---|---|---|---|
| Name | Ferulic acid NP Info | + | ABT-888 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. Biochem Biophys Res Commun. 2015 Mar 13;458(3):520-524. | |||
